Insider Buying: Zentek (CVE:ZEN) Director Buys 11,000 Shares of Stock

Zentek Ltd. (CVE:ZEN) Director Mohammed Jiwan bought 11,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was acquired at an average price of C$0.93 per share, for a total transaction of C$10,230.00. Following the completion of the acquisition, the director directly owned 22,000 shares in the company, valued at approximately C$20,460. This represents a 100.00% increase in their ownership of the stock.

Zentek Price Performance

CVE:ZEN remained flat at C$0.91 during trading hours on Wednesday. 23,946 shares of the company were exchanged, compared to its average volume of 47,973. The company has a debt-to-equity ratio of 4.97, a current ratio of 2.06 and a quick ratio of 7.59. The stock has a market cap of C$97.65 million, a P/E ratio of -10.11 and a beta of 0.42. Zentek Ltd. has a 1 year low of C$0.85 and a 1 year high of C$2.50. The stock has a 50 day moving average price of C$1.07 and a 200-day moving average price of C$1.19.

Zentek Company Profile

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis. In addition, the company owns 100% interest in the Albany graphite project located in Northern Ontario, Canada.